Last Friday, Agomab Therapeutics (Nasdaq: AGMB), an Asabys portfolio company, successfully completed its initial public offering on Nasdaq, raising approximately $200M in the IPO.
Asabys is an investor in Agomab Therapeutics through its two funds: Sabadell Asabys I (Sabadell Asabys Health Innovation Investments I SCR, SA and Asabys Top Up Fund) and Sabadell Asabys II (Sabadell Asabys Health Innovation Investments II FCR and Sabadell Asabys Health Innovation Investments 2B SCR, SA).
Their relationship with the company began in 2021, when Agomab acquired Origo Biopharma, one of their portfolio companies, marking Asabys’s first exit.
Since then, they have continued to support Agomab through participation in subsequent financing rounds (Series B extension, Series C, Series D and IPO), alongside top-tier co-investors such as Pfizer, Fidelity, Sanofi, KKR and EQT, among others. Notably, the Agomab assets that are currently in clinical stages originate from Origo, validating their initial thesis and Asabys’s investment strategy, which is based on the early creation of companies with differentiated science and transformative potential.
With this listing, Agomab Therapeutics strengthens its position in the international biotechnology arena, and Asabys consolidates its role as a reference investor in innovative healthcare companies.
cloud technology axon
Xcalibur Smart Mapping, recognised as the global leader in airborne...
Capital-Riesgo.es
Subscribe to our newsletter and stay up to date with the latest news and deals!
2013 © Capital-Riesgo.es - Site Developments SL. All Rights Reserved. Terms of Service | Privacy Policy
Articles
Directory
